The financials
GeneDx Holdings Corp. by the numbers
GeneDx Holdings Corp. (WGS) reported revenue of $102M in Q1 2026 (quarter ended March 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $63M. For the full year FY2025, revenue was $428M (+40% year on year) and net income −$21M. Its largest product in 2026-Q1 was Diagnostic Test Third Party Insurance at $85M, 84% of the disclosed total, just ahead of Diagnostic Test Institutional Customers at 15%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $102M | $87M | +17% |
| Gross profit | $68M | $58M | +17% |
| Operating income | −$57M | −$4.6M | n/a |
| Net income | −$63M | −$6.5M | n/a |
| Diluted EPS | −$2.16 | −$0.23 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Diagnostic Test Third Party Insurance | $85M | 84% |
| Diagnostic Test Institutional Customers | $16M | 15% |
| Product And Service Other | $955K | 0.9% |
| Diagnostic Test Self Pay | $286K | 0.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $101.7M (-13%)
Diagnostic Test Self Pay grew +198% year on yearProduct And Service Other -30% year on year
Segment Latestquarter on quarteryear on year
- Diagnostic Test Third Party Insurance$84.9M$84.9MQoQ -11%year on year +25%-11%+25%
- Diagnostic Test Institutional Customers$15.5M$15.5MQoQ -11%year on year -12%-11%-12%
- Product And Service Other$955.0K$955.0KQoQ -70%year on year -30%-70%-30%
- Diagnostic Test Self Pay$286.0K$286.0KQoQ -55%year on year +198%-55%+198%
Diagnostics & Research
Ranks #28 of 29 by Smart Score